USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Mumbai: Lower Parel Businessman Cheated Of ₹9 Lakh With False Promise Of SRA Flat In Prabhadevi
IND Vs SA 3rd T20I Toss Update: Suryakumar Yadav Wins Toss, Bumrah Out, Kuldeep In As India Bowl First
Mallika Sherawat Swears By These Yoga Asanas For Increased Blood Circulation & Stable Engery
Navi Mumbai To Host Inaugural CIDCO Open 2025 International Golf Tournament
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
